Does xanthelasma mean my cholesterol is high?

Not necessarily. Approximately half of xanthelasma patients have entirely normal lipid levels. Nevertheless, xanthelasma is considered a marker of cardiovascular risk regardless of cholesterol values, so a lipid profile blood test is recommended for every patient.

Will xanthelasma come back after treatment?

Recurrence is the most significant challenge in xanthelasma treatment. Depending on the method used, recurrence rates range from 40 to 60 percent. Surgical excision has the lowest recurrence rate, but no method guarantees permanent removal. Controlling lipid levels may help reduce the risk.

Can creams or medications make xanthelasma disappear?

No. Topical creams, ointments, and oral cholesterol-lowering medications do not dissolve existing xanthelasma plaques. Statins are important for overall cardiovascular health but will not remove the deposits already present. Surgical or ablative treatment is required.

Is surgical excision scarring visible?

Eyelid skin is thin and heals well. Incisions are placed along natural lid creases, so scars typically become very faint over time. Larger lesions involve more tissue removal, which can increase scar visibility. Each patient heals differently.

Which doctor should I see for xanthelasma?

An oculoplastic surgeon is the most appropriate specialist because xanthelasma forms on the eyelid. Oculoplastic surgeons have expertise in both eyelid anatomy and surgical removal techniques. Additionally, an internist or cardiologist may be consulted to evaluate underlying metabolic conditions.

Xanthelasma -- Eyelid Cholesterol Deposits

Kısa Yanıt

Xanthelasma palpebrarum are yellowish, flat or slightly raised plaques on the eyelids caused by lipid-laden macrophage deposits in the dermis. They are benign but cosmetically bothersome and may indicate an underlying lipid disorder. Treatment involves surgical excision or ablative techniques; however, recurrence rates are notable across all methods.

What Is Xanthelasma?

Xanthelasma are soft, yellowish deposits that appear most commonly near the inner corners of the eyelids. They are composed of foam cells -- macrophages that have accumulated intracellular lipid. The lesions are usually bilateral and symmetric, grow slowly, are painless, and do not resolve on their own. Over time, they may increase in size and number.

Xanthelasma belong to the broader family of xanthomas (lipid deposits in various body sites). They can occur on both the upper and lower lids, though the upper medial eyelid is the most frequent location.

Causes and Risk Factors

Hyperlipidemia: Elevated LDL cholesterol or triglycerides is the best-known risk factor, but this association is not absolute.
Genetic predisposition: A family history of xanthelasma increases the likelihood.
Diabetes mellitus: Particularly type 2 diabetes, through its effects on lipid metabolism.
Hypothyroidism: Thyroid underactivity can elevate cholesterol levels and promote xanthelasma formation.
Liver disease: Cholestatic liver conditions such as primary biliary cholangitis can increase lipid accumulation.

Important: Approximately 50 percent of patients with xanthelasma have completely normal lipid levels. Even so, xanthelasma has been linked to an increased cardiovascular risk in some studies, making metabolic screening worthwhile in every case.

Diagnosis

Diagnosis is typically clinical. The characteristic appearance -- soft, yellow, well-demarcated plaques near the medial canthi -- is usually sufficient. Additional steps include:

Lipid profile: Total cholesterol, LDL, HDL, and triglycerides should be measured in every patient.
Metabolic screening: Fasting glucose, thyroid function, and liver function tests help identify contributing conditions.
Biopsy (rarely): Histopathological examination may be warranted for atypical-appearing lesions.

Treatment Options

Surgical excision

The most widely used and effective method. The plaque is carefully excised within the eyelid under local anesthesia. The wound is closed with fine sutures. Surgical excision provides histopathological confirmation and has the lowest reported recurrence rate among available treatments.

Trichloroacetic acid (TCA) application

High-concentration TCA is applied directly to the lesion to achieve chemical ablation. Suitable for small, superficial plaques. Multiple sessions may be needed.

Laser ablation (CO2 or Er:YAG)

Laser energy vaporizes the deposit with controlled depth. It offers precision and minimal bleeding but carries a risk of pigmentation changes, especially in darker skin tones.

Cryotherapy

Liquid nitrogen freezes and destroys the tissue. Application is quick but depth control is limited, and there is a risk of scarring and pigmentation abnormalities.

All methods carry a significant recurrence risk (40-60 percent). Managing underlying lipid abnormalities may help reduce this risk.

Recovery After Surgical Excision

Days 1-3

Mild swelling and bruising around the excision site. Cold compresses and head elevation are helpful. Pain is usually minimal.

Week 1

Sutures are removed around days 5-7. Swelling and bruising decrease noticeably. Wound care instructions should be followed carefully.

Weeks 2-4

The scar begins to mature; initial redness gradually fades. Most patients can comfortably return to social activities. Sun protection is recommended.

Months 1-3

The scar becomes significantly less visible. Final cosmetic result is evaluated. Follow-up for recurrence monitoring is scheduled.

Risks and Limitations

Recurrence: The most significant limitation. Rates of 40-60 percent are reported regardless of method.
Scarring: Minimal for small lesions; larger excisions may leave a more visible scar.
Ectropion risk: Excessive tissue removal near the lower lid can cause outward lid turning.
Pigmentation changes: Especially with laser and cryotherapy techniques.
Infection: Rare, as with any surgical procedure.

Ne Zaman Acil Doktora Başvurmalı?

•Rapidly growing or spreading eyelid lesion
•Pain, ulceration, or bleeding from a previously stable plaque (atypical -- may suggest a different diagnosis)
•Plaques large enough to interfere with the visual field
•Yellowish deposits appearing on other body parts (widespread xanthomatosis may indicate a serious lipid disorder)

If you notice any of these changes, consult an oculoplastic surgeon for evaluation.

Clinical Note
The most important conversation I have with xanthelasma patients is about recurrence. Setting realistic expectations before treatment is essential -- no method guarantees permanent removal. I also recommend a lipid panel for every patient, even when the deposits appear purely cosmetic, because the metabolic information is valuable for long-term cardiovascular health. For treatment planning, lesion size and location on the eyelid guide the choice of technique; larger lesions near the lid margin require careful surgical planning to preserve eyelid function and contour.
BA
Op. Dr. Burak Akbay
Göz Hastalıkları Uzmanı | FEBO

Frequently Asked Questions

Xanthelasma Evaluation

If you have noticed yellowish plaques on your eyelids or wish to explore treatment options for existing xanthelasma, schedule a consultation.

Call WhatsApp Book Online

Memorial Bahçelievler Hastanesi, İstanbul

References & Sources

American Academy of Ophthalmology (AAO). Preferred Practice Patterns — Oculoplastic Surgery.
European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS). Clinical Guidelines.
Nerad JA. Smith and Nesi's Ophthalmic Plastic and Reconstructive Surgery. 4th ed. Springer; 2021.
PubMed — U.S. National Library of Medicine. Oculoplastic surgery literature.

This page is for general informational purposes only and does not replace medical examination, diagnosis, or treatment. Each patient should be evaluated individually. Treatment decisions can only be made after an in-person consultation.

Results of any surgical or interventional procedure may vary from person to person. The information on this site does not guarantee any specific treatment outcome.

Medical review: Op. Dr. Burak Akbay — Göz Hastalıkları Uzmanı | FEBO

Published: 13 April 2026

Last updated: 13 April 2026